Abstract
Swainson, J., McGirr, A., Blier, P., Brietzke, E., Richard-Devantoy, S., Ravindran, N., Blier, N., Beaulieu, S., Frey, B. N., Kennedy, S.H., McIntyre, R.S., Milev, R.V., Parikh, S.V., Schaffer, A. Taylor, V.H., Tourjman, V., Ameringen, M.V., Yatham, L.N., Ravindran, A.V., and Lam, R.W. Can J Psychiatry. 2021 Feb;66(2):113-125. (Original DOI: 10.1177/0706743720970860)
The Declaration of Conflict of Interests statement included for author Roger McIntyre was incomplete in the original article. The statement has been updated as follows:
Dr. Roger McIntyre has received research grant support from CIHR/GACD/Chinese National Natural Research Foundation; speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie, Shire, Allergan, and Minerva. Dr. Roger McIntyre is a CEO of Braxia Scientific Corp (previously known as Champignon), which owns The Canadian Rapid Treatment Center of Excellence (CRTCE), a group of medical clinics that provide ketamine/esketamine for persons with treatment-resistant depression.